A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).Shubham Pant, Manish R. Patel, Michael Millward et al.|Journal of Clinical Oncology|2019Cited by 24
Abstract ND06: ECI830, a potent and highly selective CDK2 inhibitor, for the treatment of HR+/HER2− breast cancer and <i>CCNE1</i> -amplified tumorsSamuel Ho, Vivek Rauniyar, Ophélia Maertens et al.|Cancer Research|2026Cited by 0